EF Hutton Reiterates Buy on VolitionRX, Maintains $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore has reiterated a Buy rating on VolitionRX (AMEX:VNRX) and maintained a price target of $4.5 for the company's stock.
November 21, 2023 | 7:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Tim Moore reaffirmed a Buy rating on VolitionRX with a price target of $4.5, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a reputable analyst like Tim Moore from EF Hutton can instill confidence in investors and potentially lead to a positive short term impact on VolitionRX's stock price. The maintained price target of $4.5 suggests that the analyst sees continued upside potential in the stock, which could influence investor sentiment and trading behavior.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100